VNDA Earnings Prediction
The chart below shows how VNDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VNDA sees a -0.29% change in stock price 10 days leading up to the earnings, and a -3.10% change 10 days following the report. On the earnings day itself, the stock moves by -1.78%. This data can give you a slight idea of what to expect for the next quarter's release.
VNDA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
53.19M
17.48%
11.61%
Gross Margin
91.84%
1.76%
0.96%
Operating Margin
-19.33%
23.36%
-16.25%
Net Margin
-9.24%
74.34%
-17.28%
EPS
-0.08
-100.00%
-11.11%
No Data Available
VNDA Earnings Analysis
Vanda Pharmaceuticals Inc Corporation (VNDA.O) Earnings Conference Call
Positive
Earnings Surprise Report: Vanda Pharmaceuticals Inc. beat earnings expectations with a reported EPS of $-0.08, surpassing the expected $-0.14.
Strong Revenue Growth: Fanapt showed strong revenue growth, with net product sales increasing by 18% in Q4 2024 compared to Q4 2023, driven by a 160% increase in new patient starts.
Fanapt Commercial Launch Expansion: The company initiated a commercial launch of Fanapt for bipolar I disorder, supported by a dedicated sales force of approximately 200 persons, which is being expanded to 300 representatives.
Anti-Inflammatory Portfolio Expansion: Vanda's anti-inflammatory portfolio was strengthened with the addition of imsidolimab, with plans to file a BLA later this year for generalized pustular psoriasis.
Revenue Increase Overview: Total revenues for the full year 2024 were $198.8 million, a 3% increase compared to $192.6 million in 2023, primarily due to increased Fanapt revenue and the introduction of Ponvory.
Product Sales Diversification: Ponvory net product sales were $27.8 million for the full year 2024, marking significant progress in diversifying Vanda's product mix.
Fanapt Revenue Projections: The company expects to achieve total revenues from Fanapt of between $210 million and $250 million in 2025, indicating a growth of 6% to 26% compared to 2024.
Psychiatry Revenue Target: Vanda is targeting annual revenue in excess of $750 million for its psychiatry portfolio by 2030, assuming potential approvals for Vantrela and Fanapt LAI.
Negative
Hetlioz Revenue Decline: Decrease in Hetlioz revenue due to generic competition, with a 23% decline from $100.2 million in 2023 to $76.7 million in 2024.
Net Loss Decline: Net loss of $18.9 million for the full year 2024, compared to a net income of $2.5 million in 2023, indicating a significant downturn in profitability.
Increased Operating Expenses: Operating expenses increased by $32.8 million in 2024, primarily driven by higher SG&A expenses related to commercial product launches, which may not yield immediate returns.
Hetlioz Sales Decline Risks: Potential for significant future declines in Hetlioz sales due to ongoing generic competition and inventory destocking at specialty pharmacies.
Cash Burn and Financial Strain: Increased cash burn with a decrease in cash, cash equivalents, and marketable securities by $13.6 million from December 31, 2023, indicating financial strain.
Revenue Variability Risks: The company may face revenue variability in future periods due to uncertainties related to inventory stocking by specialty pharmacy customers for Hetlioz.
VNDA FAQs
How does VNDA typically perform around its earnings report dates?
Is Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VNDA Earning Call Sentiment
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2024 Earnings Call Transcript
VNDA.O
-2.89%Positive
The earnings call presents mixed results: Fanapt sales increased, but Hetlioz faced a decline due to competition. The company revised its revenue guidance upwards, which is positive, but operating expenses and net loss increased. The Q&A revealed some uncertainties, like the sales force's sufficiency and delays in product filings. Overall, the market may react neutrally, balancing positive guidance and product developments with increased losses and expenses.
